Twist Bioscience Corp vs Zscaler Inc — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Zscaler Inc trades at $166.4 (market cap $26.41B). The key difference: Zscaler Inc is far larger — about 3.1× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| TWST | ZS | |
|---|---|---|
Market Cap | $8.42B | $26.41B |
Sector | Health | Technology |
52-Week High | $153.10 | $336.27 |
52-Week Low | $24.16 | $118.05 |
Enterprise Value | $8.35B | $24.79B |
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Zscaler (ZS) trades at $161.94, down 4.63% amid bearish technical signals despite strong quarterly earnings beats. The stock shows improving fundamentals with revenue growing from $1.1B in 2022 to $2.67B in 2025, though net margins remain negative. Recent news highlights Zscaler's AI security innovations and conference presentations, while analyst consensus remains strongly bullish with a $204.88 price target representing 26% upside potential.
Zscaler presents a compelling growth story with accelerating revenue and strong enterprise adoption, though profitability challenges and elevated valuation metrics warrant caution. The stock's current weakness near support levels offers potential entry points for investors bullish on cybersecurity demand, particularly given Zscaler's leadership in zero-trust security and AI-driven threat protection capabilities.
Trailing returns across standard periods
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →